BPC
CRNX icon

Bryce Point Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bryce Point Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,371
Closed -$611K – 200
2025
Q1 		$611K Sell
17,371
-5,315
-23% -$198K 0.46% 149
2024
Q4 		$1.16M Buy
+22,686
New +$1.27M 0.34% 120

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bryce Point Capital's CRNX Position: Q2 2025 in Review

Bryce Point Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 17,371 shares — an estimated $611K sold.

Bryce Point Capital first reported a position in CRNX in Q4 2024 and held it in 2 quarters. The position peaked at $1.16M in Q4 2024. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • Bryce Point Capital reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bryce Point Capital sold 17,371 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $611K.
  • Bryce Point Capital first reported a position in Crinetics Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Bryce Point Capital's Crinetics Pharmaceuticals position peaked at $1.16M in Q4 2024.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Bryce Point Capital's 13F filing for Q2 2025, filed 5 Aug 2025.